article graphic

News & insights

筛选条件:

Filters

International Life Sciences Newsletter - Life Sciences Legal Lens Vol. 2

Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”

Digital Omnibus Update. More time (up to August 2028) yet confirming that AI-enabled medical devices and IVDs stay subject to the AI Act.

2026年7月2日
Briefing

作者 Irina Rebin

4 / 9 观点

点击此处了解更多
International Life Sciences Newsletter - Life Sciences Legal Lens Vol. 2

CJEU on distributor's verification obligations under MDR

Medical device (and IVD) distributors. CJEU confirms that distributors need not repeat the manufacturer’s classification or conformity assessment, but must perform a “consistency check” for obvious inconsistencies.

2026年7月1日
Briefing

作者 Irina Rebin

1 / 9 观点

点击此处了解更多
Glass.Mapper.Sc.Fields.Image?.Alt
酒店与休闲

Landmark CJEU Decision on the Obligations of Medical Device Distributors

2026年6月23日
Briefing

作者 Dr. Daniel Tietjen 以及 Daniel Dietrich

点击此处了解更多
Glass.Mapper.Sc.Fields.Image?.Alt
酒店与休闲

CJEU Advocate General on Distributors’ Obligations for Medical Devices

2026年4月29日
Briefing

作者 Dr. Daniel Tietjen 以及 Daniel Dietrich

点击此处了解更多
International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

Proposed Amendments to the EU Medical Device Regulation

A European Perspective #1 | The Commission’s proposed MDR/IVDR reform introduces substantial changes to certification, classification and compliance frameworks. Medical device companies should assess potential im-pacts early and prepare for a shifting regulatory landscape.

2026年4月15日
Briefing

作者 Bartosz Świdrak

2 / 9 观点

点击此处了解更多
International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

A European Perspective #1 | The EU’s largest pharmaceutical law reform in over 20 years introduces a new regulatory exclusivity framework, revised orphan drug incentives and an antimicrobial voucher. Strategic exclusivity planning will become essential for pharmaceutical companies.

2026年4月15日
Briefing

作者 Irina Rebin

1 / 9 观点

点击此处了解更多
International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

No claim for damages as a result of participation in clinical drug trials

A European Perspective #1 | GERMANY | The Frankfurt am Main Regional Court confirms: No reduction in the burden of proof (presumption of causality) pursuant to Section 84 (2) of the German Medicines Act (AMG) for IMP (not even by analogy) and no liability on the part of the sponsor in the event of (insufficient) risk information provided by the investigating physician.

2026年4月1日

作者 Irina Rebin

7 / 9 观点

点击此处了解更多
International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

Promotional activities for medical devices may qualify as agency even without direct negotiation power

A European Perspective #1 | FRANCE | The French Supreme Court confirms a broad interpretation of commercial agent status. A key ruling increasing requalification risks and potential termination indemnity exposure for manufacturers and distributors.

2026年4月1日
Briefing

作者 Annabelle Lebaudy

6 / 9 观点

点击此处了解更多
Glass.Mapper.Sc.Fields.Image?.Alt
品牌与广告业

Retailer obligations under scrutiny: ECJ to clarify scope of inspection obligations

2025年11月13日
In-depth analysis

作者 Dr. Wiebke Baars, LL.M.

点击此处了解更多
Call To Action Arrow Image

Events

Hear from our experts as they discuss the latest legal issues.

Browse our events
Browse our events